Form 8-K - Current report:
SEC Accession No. 0000950170-24-075872
Filing Date
2024-06-21
Accepted
2024-06-21 07:05:38
Documents
13
Period of Report
2024-06-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20240621.htm   iXBRL 8-K 128291
2 EX-10.1 eypt-ex10_1.htm EX-10.1 111925
3 EX-10.2 eypt-ex10_2.htm EX-10.2 164866
  Complete submission text file 0000950170-24-075872.txt   562705

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20240621.xsd EX-101.SCH 23897
17 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20240621_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 241058336
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)